患者导航贯穿癌症连续照护:系统综述概览与新兴文献
该伞形综述旨在识别、严格评价、综合并呈现关于患者导航贯穿癌症连续照护的最佳证据,以用于政策与规划。检索2012年1月1日至2022年4月19日多个数据库及灰色文献,纳入61篇系统综述(54篇定量或混合方法、7篇定性)及53项2021年以来发表的原始研究。患者导航可提高癌症筛查参与率、缩短筛查至诊断及诊断至治疗启动的时间;新兴证据提示其可改善生存期生活质量与满意度、降低再入院;姑息治疗数据极为有限。
要点
- 患者导航可提高癌症筛查参与率,并缩短筛查至诊断、诊断至治疗启动的时间。
- 新兴证据提示患者导航可改善生存期生活质量与照护满意度,并降低治疗期和生存期再入院。
- 姑息治疗相关数据极为有限。
核心结论
- 患者导航可有效提高癌症筛查参与率,并缩短筛查至诊断及诊断至治疗启动的时间。
- 新兴证据提示患者导航可改善生存期生活质量与照护满意度,并降低活动治疗期和生存期照护阶段的再入院。
- 姑息治疗数据极为有限。
- 美国的卫生经济学评价提示导航在筛查项目中具有潜在成本效果。
研究设计与样本
- 伞形综述,检索Cochrane CENTRAL、PubMed、Embase、CINAHL、Epistemonikos、PROSPERO数据库及灰色文献,时间范围为2012年1月1日至2022年4月19日。
- 由两名作者独立筛选、提取和评价数据,采用JBI系统综述与研究综合关键评价清单进行质量评价。
- 探索截至2022年5月25日的新兴文献,以纳入所收系统综述覆盖范围之外发表的原始研究。
- 共识别2062条唯一记录,纳入61篇系统综述;其中54篇为定量或混合方法综述(报告癌症患者导航有效性,含12篇报告成本或成本效果结局),7篇为定性综述(探讨导航需求、障碍与体验)。
- 另纳入2021年以来发表的53项原始研究。
主要发现
- 患者导航可有效提高癌症筛查参与率,并缩短筛查至诊断及诊断至治疗启动的时间。
- 新兴证据提示患者导航可改善生存期生活质量与照护满意度,并降低活动治疗期和生存期照护阶段的再入院。
- 姑息治疗数据极为有限。
- 美国的卫生经济学评价提示导航在筛查项目中具有潜在成本效果。
局限性
- 姑息治疗数据极为有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs.
引用
- Chan RJ, Milch VE, Crawford-Williams F, et al. Patient navigation across the cancer care continuum: An overview of systematic reviews and emerging literature. CA Cancer J Clin. 2023. PMID: 37358040. doi:10.3322/caac.21788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。